Antioxidant Therapy Tested in Early Parkinson’s
Treatment with the urate precursor inosine did not result in a significant difference in the rate of clinical disease progression in early Parkinson's disease, the phase III SURE-PD3 trial showed. Clinical progression rates, measured by the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) parts I-III, were not significantly…
bubmagSeptember 14, 2021